Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi

Effectiveness of quetiapine treatment in patients with schizophrenia who didn't respond well to previous treatment (CROSBI ID 586008)

Prilog sa skupa u časopisu | sažetak izlaganja sa skupa | domaća recenzija

Kozumplik, Oliver ; Uzun, Suzana ; Mimica, Ninoslav ; Folnegović-Šmalc, Vera ; Jukić, Vlado Effectiveness of quetiapine treatment in patients with schizophrenia who didn't respond well to previous treatment // Periodicum biologorum / Vitale, Branko (ur.). 2004. str. 124-124

Podaci o odgovornosti

Kozumplik, Oliver ; Uzun, Suzana ; Mimica, Ninoslav ; Folnegović-Šmalc, Vera ; Jukić, Vlado

engleski

Effectiveness of quetiapine treatment in patients with schizophrenia who didn't respond well to previous treatment

Introduction: The atypical antipsychotic quetiapine has efficacy against the positive, negative, affective and cognitive symptoms of schizophrenia. The efficacy of quetiapine in the treatment of acute schizophrenia was demonstrated in controlled trials in vvhich quetiapine was shown to be both superior to placebo and associated with clinically meaningful improvement. Regarding efficacy against positive symptoms examination of the Brief Psychiatric Rating Scale (BPRS) positive symptom cluster in the clinical studies have shown that quetiapine treatment was associated with a greater improvement in psychopathology than placebo. Compared to placebo, clinical studies have also showned improvement by quetiapine regarding negative symptoms as measured by the Scale for the Assessment of Negative Symptoms (SANS). Quetiapine was shown to improve symptoms in patients with schizophrenia who had partiall responded to conventional antipsychotics. The aim was to assess the effectiveness of quetiapine treatment in the open-label, non- comparative, 12-week study (with flexible doses of quetiapine in patients vvith schizophrenia who had inadequate response to or intolerance of their previous antipsychotic therapy. Patients and Methods: Sixty schizophrenic patients according to DSM-IV diagnostic criteria were switched to quetiapine during hospitalisation in Vrapče Psvchiatric Hospital in the period from March to July 2003. Patients were switched due to inadequate response to or intolerance of their previous antipsychotic therapy. The Clinical Global Impression (CGI) and Positive and Negative Syndrome Scale (PANSS) vvere used in order to assess effectiveness of treatment with quetiapine. Quetiapine was introduced at dose of 50 mg on day one, follovved by 100 mg, 200 mg and 300 mg on days 2, 3, and 4. After day 4, the daily dosage was between 300 mg and 1200 mg, depending on the clinical presentation. The patients were assessed prior to initiation of quetiapine treatment, after six weeks and after twelve weeks of continuous therapy with quetiapine. Statistical significance was set to a value of p.05. Results: After twelve weeks of continuous therapy vvith quetiapine, PANSS total score significantly decreased in the group of patients who were switched to quetiapine because of inadequate response to previous antipsychotic therapy (p.05). The mean CGI severity score for ali patients improved from 3.8 (»moderately ili«) to 2.9 (»mildly ili«). Conclusion: Administration of quetiapine was clinically beneficial for the patients with schizophrenia who had inadequate response to or intolerance of their previous antipsychotic therapy.

effectiveness ; quetiapine ; schizophrenia

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o prilogu

124-124.

2004.

nije evidentirano

objavljeno

Podaci o matičnoj publikaciji

Periodicum biologorum

Vitale, Branko

Zagreb:

0031-5362

Podaci o skupu

Fourth Croatian Congress of pharmacology with international participation

poster

15.09.2004-18.09.2004

Split, Hrvatska

Povezanost rada

Kliničke medicinske znanosti

Indeksiranost